curosurf suspension endotracheal
chiesi pharmaceuticals gmbh - poractant alfa - suspension endotracheal - 80mg/ml
curosurf suspension endotracheal
chiesi farmaceutici s.p.a. - poractant alfa - suspension endotracheal - 80mg/ml
quinsair 240mg nebuliser solution ampoules
chiesi ltd - levofloxacin hemihydrate - nebuliser liquid - 100mg/1ml
kengrexal 50mg powder for concentrate for solution for injection infusion vials
chiesi ltd - cangrelor tetrasodium - powder for solution for injection - 50mg
peyona 20mgml solution for infusion ampoules
chiesi ltd - caffeine citrate - solution for infusion - 20mg/1ml
procysbi 25mg gastro-resistant capsules
chiesi ltd - mercaptamine bitartrate - gastro-resistant capsule - 25mg
procysbi 75mg gastro-resistant capsules
chiesi ltd - mercaptamine bitartrate - gastro-resistant capsule - 75mg
fostair 200micrograms/dose / 6micrograms/dose inhaler
chiesi ltd - formoterol fumarate dihydrate; beclometasone dipropionate - pressurised inhalation - 6microgram ; 200microgram
fostair nexthaler 200micrograms/dose / 6micrograms/dose dry powder inhaler
chiesi ltd - formoterol fumarate dihydrate; beclometasone dipropionate - inhalation powder - 6microgram/1dose ; 200microgram/1dose
fostair 200/6 inhalation solution
chiesi limited - beclometasone dipropionate, formoterol fumarate dihydrate. - pressurised inhalation solution. - 200/6 micrograms/metered dose - drugs for obstructive airway diseases; adrenergics, inhalants - fostair is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled rapid-acting beta2-agonist or - patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists. fostair is indicated in adults.